Rapid High-Throughput Assay Identified Gemcitabine and Derivatives As Potent Inhibitors Against Multidrug-Resistant Staphylococcus aureus

Assay Drug Dev Technol. 2022 May-Jun;20(4):175-182. doi: 10.1089/adt.2022.034.

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) are challenging pathogenic bacteria that can cause severe infection leading to high mortality rates. We found that both the oxacillin- and cefoxitin-resistant S. aureus strains isolated from clinic showed multidrug-resistant (MDR) characteristics. Through rapid high-throughput screen (HTS) of a compound library, gemcitabine and selen compounds were found to effectively inhibit S. aureus growth. For further improvement, we synthesized selen-containing gemcitabine that demonstrated relatively potent antimicrobial activity against several MDR MRSA in vitro. The HTS assay and gemcitabine selen derivative provided a useful tool to explore an effective molecular target to treat MDR MRSA.

Keywords: EZMTT-based HTS method; gemcitabine; methicillin-resistant Staphylococcus aureus; multidrug resistance; selen derivative.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Deoxycytidine / analogs & derivatives
  • Gemcitabine
  • Humans
  • Methicillin-Resistant Staphylococcus aureus*
  • Microbial Sensitivity Tests
  • Staphylococcal Infections* / microbiology
  • Staphylococcus aureus

Substances

  • Anti-Bacterial Agents
  • Deoxycytidine
  • Gemcitabine